September 30, 2021 | CRISPR, Impetus Digital, Jessica Schwaber, Natalie Yeadon, Solupore, allogeneic therapies, cell engineering, cell therapy, gene therapy, gene-editing, non-viral modalities, precision medicine, viral modalities
Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing the full potential of cell & gene therapy, and much more.
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
How Pharma can (and why they should) help bring caregivers to the forefront
Tip #1 – How can you take your online presentations to the next level? Check out the full list of top 10 tips to increase engagement during virtual events: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/
A Customer Story
Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, explores his journey from computer engineering to healthcare, innovation in the cardiac monitoring space, the concept of Mobile Cardiac Telemetry (MCT), and…
Rick Anderson, President of DarioHealth, explores digital therapeutics, how DarioHealth is utilizing AI and behavioral science to personalize each user’s health journey, and how this approach can help improve diversity…
A Customer Story
Brad Womble, Senior Director of Strategy, Marketing and Mergers & Acquisitions, at Jabil Healthcare dives into several thought-provoking topics, including how insights from “digital twins” can be used to improve…
Real-world methodology & results from hosting an ongoing, nationwide Digital Content Council…
Anthony Capone, President of DocGo, shares how his company uses last-mile mobile health services and integrated medical transportation solutions to make healthcare more accessible for everyone, including underserved populations.
Lawrence Bressler, Head of Value & Market Access, Global Rare Diseases at Chiesi, shares how Chiesi is revolutionizing the lives of people living with rare diseases on a global scale….
